Healthcare / Drug Manufacturers - Specialty & GenericShenzhen
$13.01
-0.07 (-0.54%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 19%
FCF escenarios
weak_data · normalized FCF $478.9M · quality 44.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
23/100
D
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$7.6B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-6.7%
↓Gross Margin
38.2%
↓Debt/Equity
0.03
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-23.1%
FCF CAGR
-36.0%
FCF margin
20.7%
FCF / Net income
-1.86x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $2.32B · net income $-257.8M · FCF $478.9M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $2.32B | $2.32B | $3.38B | $5.70B | $5.09B |
| Net Income | $-257.8M | $-257.8M | $492.0M | $1.12B | $867.2M |
| EBITDA | $-94.3M | $-94.3M | $819.1M | $1.54B | $1.36B |
| EPS | -0.44 | -0.44 | 0.84 | 1.92 | 1.48 |
| Gross Margin | 38.2% | 38.2% | 44.9% | 56.3% | 57.7% |
| Operating Margin | -9.1% | -9.1% | 19.7% | 22.8% | 21.8% |
| Net Margin | -11.1% | -11.1% | 14.6% | 19.6% | 17.0% |
| Balance Sheet | |||||
| Debt/Equity | 0.03 | 0.03 | 0.00 | 0.01 | 0.10 |
| Current Ratio | 3.33 | 3.33 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $478.9M | $478.9M | $-400.3M | $740.5M | $1.82B |
| Returns | |||||
| ROE | -6.7% | -6.7% | 11.2% | 23.5% | 20.6% |
| Valuation | |||||
| P/E | — | — | 23.98 | 13.41 | 17.42 |
| EV/EBITDA | — | — | 13.14 | 8.27 | 9.67 |
| P/B | 1.99 | 1.99 | 2.69 | 3.15 | 3.59 |
| Growth & Yield | |||||
| Revenue Growth | -31.4% | -31.4% | -40.8% | 11.9% | — |
| EPS Growth | -152.4% | -152.4% | -56.3% | 29.7% | — |
| Dividend Yield | 3.8% | 3.8% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-16.0%
Start / end P/E
n/dx → n/dx
EPS bridge
0.84 → -0.44
Residual
-19.8%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.